Investors Buy Large Volume of Call Options on Dermira (DERM)

Dermira Inc (NASDAQ:DERM) saw unusually large options trading on Thursday. Stock traders acquired 4,688 call options on the company. This represents an increase of approximately 5,760% compared to the average daily volume of 80 call options.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in Dermira by 469.9% in the fourth quarter. Bank of America Corp DE now owns 2,172,328 shares of the biopharmaceutical company’s stock valued at $15,619,000 after purchasing an additional 1,791,178 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Dermira by 2.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 943,421 shares of the biopharmaceutical company’s stock valued at $6,783,000 after purchasing an additional 22,816 shares during the last quarter. Sofinnova Ventures Inc increased its holdings in Dermira by 35.9% in the third quarter. Sofinnova Ventures Inc now owns 495,293 shares of the biopharmaceutical company’s stock valued at $5,399,000 after purchasing an additional 130,953 shares during the last quarter. First Midwest Bank Trust Division increased its holdings in Dermira by 31.2% in the fourth quarter. First Midwest Bank Trust Division now owns 443,625 shares of the biopharmaceutical company’s stock valued at $3,190,000 after purchasing an additional 105,565 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Dermira by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 392,484 shares of the biopharmaceutical company’s stock valued at $2,821,000 after purchasing an additional 12,060 shares during the last quarter. Institutional investors and hedge funds own 85.74% of the company’s stock.

NASDAQ DERM opened at $7.07 on Friday. The company has a debt-to-equity ratio of 5.21, a current ratio of 5.29 and a quick ratio of 5.25. Dermira has a 12 month low of $6.00 and a 12 month high of $27.83.

A number of equities research analysts have recently weighed in on DERM shares. Zacks Investment Research upgraded Dermira from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research report on Wednesday, January 23rd. Cantor Fitzgerald set a $20.00 target price on Dermira and gave the stock a “buy” rating in a research report on Friday, December 28th. BidaskClub downgraded Dermira from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 15th. Guggenheim restated a “buy” rating and set a $20.00 target price on shares of Dermira in a research report on Tuesday, November 20th. Finally, HC Wainwright started coverage on Dermira in a research report on Thursday, February 14th. They set a “buy” rating and a $13.00 target price for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $14.90.

TRADEMARK VIOLATION NOTICE: “Investors Buy Large Volume of Call Options on Dermira (DERM)” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.themarketsdaily.com/2019/02/22/investors-buy-large-volume-of-call-options-on-dermira-derm.html.

Dermira Company Profile

Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.

See Also: How do investors use RSI to grade stocks?

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply